Skip to search formSkip to main contentSkip to account menu

lazabemide

National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

Antiparkinson AgentsMonoamine Oxidase InhibitorsPicolinic Acids

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2003
2003
Mapping the Cerebral Monoamine Oxidase Type A: Positron Emission Tomography Characterization of the Reversible Selective Inhibitor [11C]Befloxatone
Befloxatone is a competitive and reversible inhibitor of monoamine oxidase-A (MAOI-A). The aim of the study was to characterize… 
2002
2002
Lazabemide, a selective, reversible monoamine oxidase B inhibitor, as an aid to smoking cessation.
BACKGROUND Previous research has shown that smokers have reduced brain and platelet monoamine oxidase B (MAOB) activity. This is… 
2002
2002
Characterization of the discriminable stimulus produced by 2‐BFI: effects of imidazoline I2‐site ligands, MAOIs, β‐carbolines, agmatine and ibogaine
The molecular nature and functions of the I2 subtype of imidazoline binding sites are unknown but evidence suggests an… 
2000
2000
Monoamine oxidase inhibitors reduce conditioned fear stress-induced freezing behavior in rats.
1997
1997
Densities of I2-imidazoline receptors, α 2-adrenoceptors and monoamine oxidase B in brains of suicide victims
1997
1997
Pharmacokinetics and pharmacodynamics of single and multiple doses of the MAO-B inhibitor lazabemide in healthy subjects.
AIMS The objectives of this study were to assess the tolerability, pharmacokinetics and pharmacodynamics of the reversible… 
Highly Cited
1997
Highly Cited
1997
Increased Density of Catalytic Sites and Expression of Brain Monoamine Oxidase A in Humans with Hepatic Encephalopathy
Abstract: Altered biogenic amine metabolism and function are believed to underlie certain of the neuropsychiatric symptoms, e.g… 
Highly Cited
1996
Highly Cited
1996
Effect of lazabemide on the progression of disability in early Parkinson's disease
Lazabemide (Ro 19‐6327) is a relatively short‐acting, reversible, and selective type B monoamine oxidase inhibitor that is not… 
1993
1993
A controlled trial of lazabemide (RO19–6327) in untreated Parkinson's disease
The monoamine oxidase type B inhibitor deprenyl (selegiline) has been demonstrated to delay the emergence of disability in early… 
1993
1993
Symptomatic anti-parkinsonian effects of monoamine oxidase-B inhibition: comparison of selegiline and lazabemide.
: Selegiline (deprenyl) and lazabemide (Ro 19-6327) are inhibitors of monoamine oxidase-B but differ in several other… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)